IDEAYA Biosciences, Inc. $IDYA Shares Acquired by UBS Group AG

UBS Group AG lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,085,632 shares of the company’s stock after buying an additional 29,055 shares during the quarter. UBS Group AG owned 1.24% of IDEAYA Biosciences worth $37,530,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Arizona State Retirement System grew its position in IDEAYA Biosciences by 1.5% in the third quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after acquiring an additional 353 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of IDEAYA Biosciences by 16.1% in the third quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after purchasing an additional 537 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in IDEAYA Biosciences by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,260 shares of the company’s stock valued at $147,000 after purchasing an additional 872 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $28.24 on Friday. IDEAYA Biosciences, Inc. has a 12 month low of $16.84 and a 12 month high of $39.28. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -17.65 and a beta of -0.04. The company’s fifty day moving average price is $32.00 and its two-hundred day moving average price is $32.96.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. The business’s revenue was down 39.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.82) earnings per share. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.15 EPS for the current year.

Wall Street Analyst Weigh In

IDYA has been the topic of several analyst reports. Guggenheim lifted their price target on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. The Goldman Sachs Group lifted their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 14th. Truist Financial set a $65.00 price target on IDEAYA Biosciences in a research note on Monday, April 13th. Finally, Citigroup increased their price target on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.69.

Insider Buying and Selling

In other news, Director Jeffrey Stein acquired 50,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This represents a 1,167.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.50% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.